MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
208.59
-0.61
-0.29%
Opening 12:57 11/29 EST
OPEN
209.50
PREV CLOSE
209.20
HIGH
212.66
LOW
208.53
VOLUME
113.11K
TURNOVER
12.90M
52 WEEK HIGH
236.80
52 WEEK LOW
117.58
MARKET CAP
25.66B
P/E (TTM)
-21.3474
1D
5D
1M
3M
1Y
5Y
Insider Sell: Alnylam Pharmaceuticals
Insider Sell: Alnylam Pharmaceuticals
MT Newswires · 6d ago
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
CAMBRIDGE, Mass., November 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Business Wire · 11/09 13:00
SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $145
Benzinga · 11/07 11:43
--SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $145 From $142, Maintains Market Perform Rating
--SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $145 From $142, Maintains Market Perform Rating
MT Newswires · 11/07 10:26
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
Benzinga · 11/02 14:21
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Benzinga · 11/02 13:43
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $415
Benzinga · 11/02 10:40
--HC Wainwright Cuts Price Target for Alnylam Pharmaceuticals to $415 From $430, Maintains Buy Rating
--HC Wainwright Cuts Price Target for Alnylam Pharmaceuticals to $415 From $430, Maintains Buy Rating
MT Newswires · 11/02 10:20
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.